AI-extracted claim
“The first patient in the Paradromics trial has primary lateral sclerosis.”
Analyzed on 2026-09-19T04:40:14+00:00 · Last updated 2026-09-19
Plain language: Insufficient evidence was found to render a verdict.
Credibility score
out of 100
Based on 1 source
Low confidence
Original context
Show passage from source article
The patient, whose name was not disclosed, has primary lateral sclerosis, which weakens neurons that control movement for talking, swallowing and walking.
Extracted from: ‘I Have a Lot to Say’: Brain Implant Helps a Disabled Patient Speak , The New York Times
Evidence
This analysis is based on a single source. Confidence is low.
Bias distribution of supporting sources
Mean bias -0.20
Community Takes
No Takes have been written on this claim yet. Sign in to write a Take.